Journal club

Journal club

Breast Cancer

Explore All
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer
Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 Study
Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 Study
EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani
EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani
EMERALD Ph III Study in discussion w/(now FDA Approved) Dr. Aditya Bardia
EMERALD Ph III Study in discussion w/(now FDA Approved) Dr. Aditya Bardia
DESTINY-Breast04 Study Discussion with Dr. Shanu Modi
DESTINY-Breast04 Study Discussion with Dr. Shanu Modi

GI

Explore All
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
FDA Approval of Cabozantinib - CABINET in pNET and epNET
FDA Approval of Cabozantinib - CABINET in pNET and epNET
FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers
FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers
FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation
FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation
FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant
FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant
FRESCO2 Study: FDA Approval of Fruquintinib for Refractory Colorectal Cancer
FRESCO2 Study: FDA Approval of Fruquintinib for Refractory Colorectal Cancer
MOUNTAINEER Study in discussion w/ Dr. Tanios Bekaii-Saab
MOUNTAINEER Study in discussion w/ Dr. Tanios Bekaii-Saab
The NICHE-2 Study Discussion with Dr. Myriam Chalabi
The NICHE-2 Study Discussion with Dr. Myriam Chalabi

GU

Explore All
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo
FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo
Breakthrough in Bladder Cancer: FDA approval – Enfortumab Vedotin + Pelbrolizumab with Dr. Tom Powles
Breakthrough in Bladder Cancer: FDA approval – Enfortumab Vedotin + Pelbrolizumab with Dr. Tom Powles
EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab
EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab

Hematology

Explore All
AGAVE-201 Study - FDA Approval of Axatilimab for Chronic Graft-versus-Host Disease (cGVHD)
AGAVE-201 Study - FDA Approval of Axatilimab for Chronic Graft-versus-Host Disease (cGVHD)
Zanubrutinib – FDA Approval, Efficacy & Safety Profile – Discussion with Dr. Shadman
Zanubrutinib – FDA Approval, Efficacy & Safety Profile – Discussion with Dr. Shadman
Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin’s Lymphoma Dr. Jonathan Friedberg
Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin’s Lymphoma Dr. Jonathan Friedberg

Lung Cancer

Explore All
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands
FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands
FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial
FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial
DeLLphi-301 - FDA Approval of Tarlatamab in Patients with Previously Treated Small Cell Lung Cancer (SCLC)
DeLLphi-301 - FDA Approval of Tarlatamab in Patients with Previously Treated Small Cell Lung Cancer (SCLC)
AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung Cancer
AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung Cancer

This website uses Cookies to ensure you receive the best experience.